Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons

Ex-vivo response to blood products and haemostatic agents after paediatric cardiac surgery

(2013) Anne-Mette Hvas et al.   BLOOD COAGULATION & FIBRINOLYSIS

Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support

(2013) Andrew J. Boyle et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Blood conservation strategies reduce the need for transfusions in ascending and aortic arch surgery

(2013) MWA Chu et al.   PERFUSION-UK

How I treat heparin-induced thrombocytopenia

(2012) A. Cuker et al.   BLOOD

Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients

(2012) C.-J. Jakobsen et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

(2011) T. J. Povsic et al.   EUROPEAN HEART JOURNAL

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

(2011) T. J. Povsic et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

(2010) Mauricio G. Cohen et al.   CIRCULATION

Morbidity and Mortality Risk Factors in Adults With Congenital Heart Disease Undergoing Cardiac Reoperations

(2009) Alessandro Giamberti et al.   ANNALS OF THORACIC SURGERY

Reoperation for Bleeding in Patients Undergoing Coronary Artery Bypass Surgery

(2009) Rajendra H. Mehta et al.  

Serious Anaphylactic Reactions due to Protamine Sulfate: A Systematic Literature Review

(2008) Mads Nybo et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI

(2008) E. I. Tucker et al.   BLOOD

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

(2008) M. Y. CHAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS